| 1 |
Fellah S, Larrue R, Truchi M, Vassaux G, Mari B, Cauffiez C, Pottier N. Pervasive role of the long noncoding RNA DNM3OS in development and diseases. Wiley Interdiscip Rev RNA 2023;14:e1736. [PMID: 35491542 DOI: 10.1002/wrna.1736] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 2 |
Lin J, Wang S, Lan W, Ji M, Li M. Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma. Sci Rep 2023;13:1897. [PMID: 36732657 DOI: 10.1038/s41598-023-29116-8] [Reference Citation Analysis]
|
| 3 |
Shao L, Liu J, Song Y, Yang W, Gong L, Lyu Z, Zhu Q, Fu J, Li J, Shi J. Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD). Clin Chim Acta 2023;538:203-10. [PMID: 36549641 DOI: 10.1016/j.cca.2022.12.014] [Reference Citation Analysis]
|
| 4 |
Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, Santos A, Armendariz-Borunda J. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers (Basel) 2022;15. [PMID: 36612019 DOI: 10.3390/cancers15010023] [Reference Citation Analysis]
|
| 5 |
Dou Q, Grant AK, Callahan C, Coutinho de Souza P, Mwin D, Booth AL, Nasser I, Moussa M, Ahmed M, Tsai LL. PFKFB3-mediated Pro-glycolytic Shift in Hepatocellular Carcinoma Proliferation. Cell Mol Gastroenterol Hepatol 2023;15:61-75. [PMID: 36162723 DOI: 10.1016/j.jcmgh.2022.09.009] [Reference Citation Analysis]
|
| 6 |
Li X, Qin Y, Kong L, Yan X, Zhang W, Martyniuk CJ, Wang X, Yan B. Metabolomic and bioenergetic responses of human hepatocellular carcinoma cells following exposure to commercial copper hydroxide nanopesticide. Environ Sci : Nano 2022;9:589-605. [DOI: 10.1039/d1en00790d] [Reference Citation Analysis]
|
| 7 |
Geyer T, Rübenthaler J, Alunni-Fabbroni M, Schinner R, Weber S, Mayerle J, Schiffer E, Höckner S, Malfertheiner P, Ricke J. NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial. Cancers (Basel) 2021;13:2787. [PMID: 34205110 DOI: 10.3390/cancers13112787] [Reference Citation Analysis]
|
